TAPO in first‐line osimertinib therapy and continuation of osimertinib

BACKGROUND: Osimertinib is associated with a relatively high frequency of drug‐induced interstitial lung disease (D‐ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequency of TAPO during first‐line treatment and the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Chihiro, Kaneshiro, Kazumi, Fujimoto, Shodai, Dokuni, Ryota, Iwamoto, Natsuhiko, Matsumura, Kanoko, Hatakeyama, Yukihisa, Kono, Yuko, Tachihara, Motoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968596/
https://www.ncbi.nlm.nih.gov/pubmed/36578073
http://dx.doi.org/10.1111/1759-7714.14782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968596/
https://www.ncbi.nlm.nih.gov/pubmed/36578073
http://dx.doi.org/10.1111/1759-7714.14782

Ejemplares similares